alexa A RANDOMISED PLACEBO CONTROLLED TRIAL TO COMPARE THE EFFECTS OF TWO DOSAGES OF OMEGA-3 PUFA ON EXERCISE-INDUCED BRONCHOCONSTRICTION (EIB)
Immunology

Immunology

Journal of Allergy & Therapy

Author(s): NC Williams, K Hunter, MA Johnson, GR Sharpe

Abstract Share this page

Treatment of EIB often involves drug interventions, but long-term use may cause systemic side effects (Dahl, Respir Med 2006;8:1307–1317). Supplementing the diet of EIB sufferers with fish oil rich in omega-3 (ω-3) polyunsaturated fatty acids (PUFA) improved post-exercise lung function and reduced systemic markers of inflammation and the need for bronchodilator use (Mickleborough et al. Am J Respir Crit Care Med 2003;168:1181–1189; Mickleborough et al. Chest 2006;129:39–49). However, these studies used high dosages of ω-3 PUFA (5–6 g·day−1), so we examined (and report preliminary data for) the effects of two different dosages of ω-3 PUFA on EIB in asthmatics. Six physically active EIB positive (≥ −10%ΔFEV1 after eucapnic voluntary hyperventilation, EVH) males and 6 (age and activity matched) non-EIB males (CTRL) volunteered for the randomised, double-blind placebo (PLA) controlled crossover study. Subjects completed (in a counterbalanced fashion) three 21 day experimental conditions: (A) HIGH dose: 6.2 g·day−1 ω-3 PUFA (3.7 g EPA, 2.5 g DHA) (B) HALF dose 3.1 g·day−1 (1.8 g EPA, 1.3 g DHA) and (C) PLA (medium chain triglyceride). EIB response to EVH was assessed on days 0 and 21, with a 14 day washout period between conditions. For CTRLs, FEV1 was not different after EVH within or between conditions. In the EIB group, the %ΔFEV1 at 6-min post-EVH was improved equally after HIGH and HALF, both being better than PLA (P<0.05): at day 21 the %ΔFEV1 6 min post-EVH was −32±20% (PLA), −21±18% (HIGH), and −19±18% (HALF). From day 0 to 21, %ΔFEV1 at 6 min post-EVH showed 38±16% and 36±21% improvements for HIGH and HALF respectively and PLA showed no change (−6±19%) (P>0.05). These data suggest that lower dosages (3.1 g·day−1) of ω-3 PUFA are as effective in aiding the treatment of EIB as high (6.2 g·day−1) dosages.

This article was published in Br J Sports Med and referenced in Journal of Allergy & Therapy

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

generalsci_health[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords